NR1H4 and metabolic dysfunction-associated steatohepatitis: The first in class FXR agonist obeticholic acid (OCA)6 has revealed very promising effects of pharmacological FXR activation in non-alcoholic steatohepatitis (NASH), in primary biliary cholangitis (PBC) and in diabetes.